Hyejeong Shin1, Lucky G Ngwira2,3, Austin Tucker1, Richard E Chaisson4, Elizabeth L Corbett2,5, David W Dowdy1,4. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. HIV and TB Group, Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi. 3. Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK. 4. Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.
Abstract
OBJECTIVES: To mitigate the economic burden of tuberculosis (TB), it is important to fully understand the costs of TB treatment from the patient perspective. We therefore sought to quantify the patient-incurred cost of TB treatment in rural Malawi, with specific focus on costs borne by patients requiring inpatient hospitalisation. METHODS: We conducted a cross-sectional survey of 197 inpatients and 156 outpatients being treated for TB in rural Malawi. We collected data on out-of-pocket costs and lost wages, including costs to guardians. Costs for inpatient TB treatment were estimated and compared to costs for outpatient TB treatment. We then explored the equity distribution of inpatient TB treatment cost using concentration curves. RESULTS: Despite free government services, inpatients were estimated to incur a mean of $137 (standard deviation: $147) per initial TB episode, corresponding to >50% of annual household spending among patients in the lowest expenditure quintile. Non-medical hospitalisation costs accounted for 88% of this total. Patients treated entirely as outpatients incurred estimated costs of $25 (standard deviation: $15) per episode. The concentration curves showed that, among individuals hospitalised for an initial TB episode, poorer patients shouldered a much greater proportion of inpatient TB treatment costs than wealthier ones (concentration index: -0.279). CONCLUSION: Patients hospitalised for TB in resource-limited rural Malawi experience devastating costs of TB treatment. Earlier diagnosis and treatment must be prioritised if we are to meet goals of effective TB control, avoidance of catastrophic costs and provision of appropriate patient-centred care in such settings.
OBJECTIVES: To mitigate the economic burden of tuberculosis (TB), it is important to fully understand the costs of TB treatment from the patient perspective. We therefore sought to quantify the patient-incurred cost of TB treatment in rural Malawi, with specific focus on costs borne by patients requiring inpatient hospitalisation. METHODS: We conducted a cross-sectional survey of 197 inpatients and 156 outpatients being treated for TB in rural Malawi. We collected data on out-of-pocket costs and lost wages, including costs to guardians. Costs for inpatient TB treatment were estimated and compared to costs for outpatient TB treatment. We then explored the equity distribution of inpatient TB treatment cost using concentration curves. RESULTS: Despite free government services, inpatients were estimated to incur a mean of $137 (standard deviation: $147) per initial TB episode, corresponding to >50% of annual household spending among patients in the lowest expenditure quintile. Non-medical hospitalisation costs accounted for 88% of this total. Patients treated entirely as outpatients incurred estimated costs of $25 (standard deviation: $15) per episode. The concentration curves showed that, among individuals hospitalised for an initial TB episode, poorer patients shouldered a much greater proportion of inpatient TB treatment costs than wealthier ones (concentration index: -0.279). CONCLUSION: Patients hospitalised for TB in resource-limited rural Malawi experience devastating costs of TB treatment. Earlier diagnosis and treatment must be prioritised if we are to meet goals of effective TB control, avoidance of catastrophic costs and provision of appropriate patient-centred care in such settings.
Authors: Lucky G Ngwira; Elizabeth L Corbett; McEwen Khundi; Grace L Barnes; Austin Nkhoma; Michael Murowa; Silvia Cohn; Lawrence H Moulton; Richard E Chaisson; David W Dowdy Journal: Clin Infect Dis Date: 2019-03-19 Impact factor: 9.079
Authors: N Stracker; C Hanrahan; L Mmolawa; B Nonyane; R Tampi; A Tucker; N West; L Lebina; N Martinson; D Dowdy Journal: Int J Tuberc Lung Dis Date: 2019-06-01 Impact factor: 2.373
Authors: V Mauch; F Bonsu; M Gyapong; E Awini; P Suarez; B Marcelino; R E Melgen; K Lönnroth; N V Nhung; N B Hoa; E Klinkenberg Journal: Int J Tuberc Lung Dis Date: 2013-03 Impact factor: 2.373
Authors: Natsayi Chimbindi; Jacob Bor; Marie-Louise Newell; Frank Tanser; Rob Baltussen; Jan Hontelez; Sake J de Vlas; Mark Lurie; Deenan Pillay; Till Bärnighausen Journal: J Acquir Immune Defic Syndr Date: 2015-10-01 Impact factor: 3.771
Authors: Stéphane Verguet; Carlos Riumallo-Herl; Gabriela B Gomez; Nicolas A Menzies; Rein M G J Houben; Tom Sumner; Marek Lalli; Richard G White; Joshua A Salomon; Ted Cohen; Nicola Foster; Susmita Chatterjee; Sedona Sweeney; Inés Garcia Baena; Knut Lönnroth; Diana E Weil; Anna Vassall Journal: Lancet Glob Health Date: 2017-11 Impact factor: 26.763